Global Respiratory Syncytial Virus-Related Infant Community Deaths.
Clin Infect Dis
; 73(Suppl_3): S229-S237, 2021 09 02.
Article
em En
| MEDLINE
| ID: mdl-34472576
ABSTRACT
BACKGROUND:
Respiratory syncytial virus (RSV) is a leading cause of pediatric death, with >99% of mortality occurring in low- and lower middle-income countries. At least half of RSV-related deaths are estimated to occur in the community, but clinical characteristics of this group of children remain poorly characterized.METHODS:
The RSV Global Online Mortality Database (RSV GOLD), a global registry of under-5 children who have died with RSV-related illness, describes clinical characteristics of children dying of RSV through global data sharing. RSV GOLD acts as a collaborative platform for global deaths, including community mortality studies described in this supplement. We aimed to compare the age distribution of infant deaths <6 months occurring in the community with in-hospital.RESULTS:
We studied 829 RSV-related deaths <1 year of age from 38 developing countries, including 166 community deaths from 12 countries. There were 629 deaths that occurred <6 months, of which 156 (25%) occurred in the community. Among infants who died before 6 months of age, median age at death in the community (1.5 months; IQR 0.8-3.3) was lower than in-hospital (2.4 months; IQR 1.5-4.0; Pâ <â .0001). The proportion of neonatal deaths was higher in the community (29%, 46/156) than in-hospital (12%, 57/473, Pâ <â 0.0001).CONCLUSIONS:
We observed that children in the community die at a younger age. We expect that maternal vaccination or immunoprophylaxis against RSV will have a larger impact on RSV-related mortality in the community than in-hospital. This case series of RSV-related community deaths, made possible through global data sharing, allowed us to assess the potential impact of future RSV vaccines.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vírus Sincicial Respiratório Humano
/
Infecções por Vírus Respiratório Sincicial
/
Vacinas contra Vírus Sincicial Respiratório
Limite:
Child
/
Humans
/
Infant
/
Newborn
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article